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Abstract
Objective: The purpose of this study was to assess whether severe overweight schizophrenic
treated patients differ from controls and from pairs in binge eating symptomatology.
Method:  Current body mass index (BMI) and the binge eating status were assessed cross-
sectionally in 40 schizophrenic outpatients and 40 non-psychiatric controls. In each group half of
the subjects were severe overweight (BMI ≥ 28) or obese.
Results:  Pearson Chi-square analysis shows a higher number of subjects with binge
symptomatology in the group of patients with schizophrenia having BMI ≥ 28 (Pearson Chi-square
= 8.67, p = 0.034). Among subjects with BMI ≥ 28, 60% of patients with schizophrenia and 30% of
controls have binge eating symptomatology.
Conclusion:  T h i s  r e s u l t  m a y  o d d s  t o  t h e  u n d e r s t a n ding of weight gain associated with
antipsychotics and underscores the importance of assessing binge eating behaviour during
treatment and prevention of obesity in this population.
Background
Weight gain (WG) induced by Antipsychotic drugs (AP)
occurs in up to 50 % of patients under chronic adminis-
tration of such medication [1]. The mechanisms of AP
causing WG are complex as they also involve serotoniner-
gic, histaminergic, dopaminergic and adrenergic neuro-
transmissions [1]. The WG is mediated by an increase in
global caloric intake, probably due to appetite and/or sati-
ety alterations [2].
Patients frequently reported their problems associated
with WG such as reduced self-esteem and repeated unsuc-
cessful dietary trials [3,4] as attempts to counterregulate
weight gain arising during AP therapy.
Binge eating disorder (BED) is a provisional new eating
disorder diagnosis [5] described in the DSM-IV research
criteria. It is characterized as a pattern of recurrent epi-
sodes of binge eating in the absence of extreme weight
control measures. Those episodes occur (at least twice a
weekly over a 6 month period to met the diagnostic crite-
ria as outlined in DSM-IV. This disorder have a prevalence
rates of 23–55% in individuals seeking treatment for
obesity compared to 2–3% in community samples [6,7].
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In the obese population, binge eaters differ from non
binge eaters in aspects of eating disorder psychopathology
and psychiatric co-morbidity [8,9]. Increased perception
of poor body image and lower weight self efficacy are sig-
nificantly related to BED [7]. Furthermore, binge eaters
tend to experience a higher level of emotional distress
[10]. Those characteristics argue for an assessment of this
eating disorder in patients with schizophrenia, a popula-
tion more vulnerable to distress and low self esteem. A
previous descriptive study found a high prevalence of BED
(12,2%) in psychotic patients treated by clozapine or
olanzapine, especially in the high body mass index (BMI)
subgroup [3].
The purpose of this study is to assess binge eating symp-
tomatology in a group of individuals receiving treatment
for schizophrenia and a group of non-psychiatric controls.
The groups were delineated by BMI for a comparison
between individuals with high and average weight.
Methods
Subjects
The study sample consisted of 40 schizophrenic (DSM-IV)
outpatients (19 female, mean age 33.8 ± 9.1) and 40 non-
psychiatric controls (21 female, mean age 35.5 ± 10.8).
Both groups were each composed of two subgroups: one
severely overweight subgroup (defined as a BMI > 28),
and a comparison sample (BMI < 28). All patients with
schizophrenia were treated by atypical AP. The WG
induced by AP drugs is not necessarily associated to obes-
ity. Due to this consideration, the threshold of BMI = 28
was chosen.
The recruitment procedure was as follows: The study was
systematically proposed during regular consultation to
outpatients with schizophrenia until reaching 20 patients
in each of the BMI subgroups. In total, the study was pro-
posed to 41 outpatients over a 6 month period. Only one
patient with obesity has refused to participate in the study.
Controls consisted of clinic workers, informed through
local advertising.
Participants gave informed consent and local Ethical
Committee approval was obtained for the study.
Design and measures
The present survey was established as a cross-sectional
case-control study. Subjects' BMI was calculated as weight
in kilograms divided by the square of height in meters.
Binge eating status was assessed through a clinical inter-
view, using DSM-IV criteria (SCID-IV) [11]. To be able to
correctly identify binge eating episodes and frequency,
detailed description of the binge eating behaviour was
obtained from each subject by a senior psychiatrist or psy-
chologist. Purging and other compensatory behaviours
were also investigated. With regard to this assessment,
patients and controls were classified as having (1)no
bingeing, (2) binge episodes less than 2 days per week
(BS), (3) BED or (4) bulimia nervosa (BN).
Psychiatric status was assessed through a chart review,
medical doctor referee and psychiatrist interview.
Data analyses
Statistical analysis was performed by SPSS 12.0 program.
An initial exploratory analysis involved calculation of
means and standard deviation for age, gender and BMI.
Differences between the groups were tested using
Kruskall-Wallis nonparametric test (for age and BMI) and
chi-square tests (for gender).
Group differences in the BED and the BS prevalence were
compared using the Pearson Chi-square test.
Results
The characteristics of the 4 groups are shown in Table 1.
Kruskal Wallis test revealed no differences with regard to
age (f = 1.2, df = 3, p = 0.16). No significant differences
were found with regard to gender distribution (Chi2 = 2.8,
df = 3, p = 0.42). As expected by the study design, Kruskal
wallis non parametric test, shows a statistically significant
BMI difference between groups (p < 0.0001), whereas no
difference was shown between high BMI schizophrenic
and non schizophrenic groups (p = 0.93).
Table 1: Characteristics of the 4 groups N = 80
Patients with schizophrenia Non-psychiatric subjects
BMI < 28 BMI ≥ 28 BMI < 28 BMI ≥ 28
N = 20 N = 20 N = 20 N = 20
Age (mean ± sd) 31.7 ± 9.2 36.1 ± 8.9 33.9 ± 13.0 37.2 ± 8.1
BMI (mean ± sd) 23.6 ± 2.2 32.9 ± 6.1 21.1 ± 2.5 33.8 ± 4.9
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Binge eating status is shown in Table 2. We found that 17/
40 of patients with schizophrenia and 10/40 of controls
have binge eating symptomatology (BS or BED). Pearson
Chi-square analysis shows a higher number of subjects
with binge symptomatology in the group of patients with
schizophrenia having BMI ≥ 28 (Pearson Chi-square =
8.67, p = 0.034). Among subjects with BMI ≥ 28, 60% of
patients with schizophrenia and 30% of controls have
binge eating symptomatology.
Discussion
The results in this study indicate that BED and BS are com-
mon behavior among overweight individuals with schiz-
ophrenia undergoing antipsychotic drug treatment. This
finding confirms previous observations of high BED rates
in the high BMI schizophrenic patient subgroup [12]. The
principal finding of this study is the significantly higher
BED and BS prevalence in the high BMI schizophrenic
group than in their relative controls. This phenomenon
observed in patients with schizophrenia having BMI ≥ 28
kg/m2, indicating that this symptomatology is not a spe-
cific correlate of antipsychotic treatment or schizophrenia
but a clinical correlate of high BMI in those patients.
We can hypothesise that in certain triggered conditions
(WG induced by antipsychotic drugs), patients with schiz-
ophrenia are more likely to develop BED and BS. This
phenomena may be due to a higher level of emotional
vulnerability, a predisposing factor to both severe over-
weight, BED and BS [13]. The conjunction of these factors
could explain the relatively high level of binge eating
symptoms observed in this study.
Due to absence of non schizophrenic psychiatric controls
and the correlation nature of this study, we cannot caus-
ally link intake of antipsychotic drugs, BED, BS and WG.
Limitations of this study included the small number of
controls in regard to the prevalence of BED in non over-
weight patients; unknown AP drugs adherence; absence of
prospective design as well as absence of non schizo-
phrenic psychiatric controls.
Nevertheless, the present results suggest that binge eating
symptomatology may play an important role in the initi-
ation and maintenance of the WG phenomenon observed
in at least part of patients with schizophrenia. Finally,
management of AP induced WG should take into account
possible comorbid binge eating symptomatology leading
to consider specific therapies such as cognitive and behav-
ioural treatment adapted to those patients.
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